| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.CCR.2009.03.003 |
| P8608 | Fatcat ID | release_hrzwnyymcvh7blkballtlltep4 |
| P698 | PubMed publication ID | 19411067 |
| P5875 | ResearchGate publication ID | 24397635 |
| P50 | author | Alan Fersht | Q537479 |
| Dmitry B Veprintsev | Q42290924 | ||
| Pierre Hainaut | Q50585710 | ||
| Klas Wiman | Q57419790 | ||
| Vladimir J N Bykov | Q88401820 | ||
| P2093 | author name string | Jan Bergman | |
| Dan Segerbäck | |||
| Jeremy M R Lambert | |||
| Dimitry B Veprintsev | |||
| Maja Söderqvist | |||
| Petr Gorzov | |||
| P433 | issue | 5 | |
| P304 | page(s) | 376-388 | |
| P577 | publication date | 2009-05-01 | |
| P1433 | published in | Cancer Cell | Q280018 |
| P1476 | title | PRIMA-1 reactivates mutant p53 by covalent binding to the core domain | |
| P478 | volume | 15 |
| Q39731280 | 15-Deoxy-Delta(12,14)-prostaglandin J(2) stabilizes, but functionally inactivates p53 by binding to the cysteine 277 residue |
| Q37247680 | 2-Sulfonylpyrimidines: Mild alkylating agents with anticancer activity toward p53-compromised cells |
| Q35879138 | 3-BrPA eliminates human bladder cancer cells with highly oncogenic signatures via engagement of specific death programs and perturbation of multiple signaling and metabolic determinants. |
| Q38774791 | A High-Throughput Cell-Based Screen Identified a 2-[(E)-2-Phenylvinyl]-8-Quinolinol Core Structure That Activates p53. |
| Q34136632 | A biomimetic polyketide-inspired approach to small-molecule ligand discovery |
| Q41905212 | A common p53 mutation (R175H) activates c-Met receptor tyrosine kinase to enhance tumor cell invasion |
| Q92856128 | A personalized approach to acute myeloid leukemia therapy: current options |
| Q91272659 | A view on drug resistance in cancer |
| Q90168991 | APR-246 alone and in combination with a phosphatidylserine-targeting antibody inhibits lung metastasis of human triple-negative breast cancer cells in nude mice |
| Q35667409 | APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells |
| Q38851714 | APR-246 potently inhibits tumour growth and overcomes chemoresistance in preclinical models of oesophageal adenocarcinoma |
| Q52579544 | APR-246 reactivates mutant p53 by targeting cysteines 124 and 277. |
| Q28284341 | APR-246/PRIMA-1(MET) rescues epidermal differentiation in skin keratinocytes derived from EEC syndrome patients with p63 mutations |
| Q37577458 | APR-246/PRIMA-1MET inhibits thioredoxin reductase 1 and converts the enzyme to a dedicated NADPH oxidase |
| Q91584678 | Abnormal accumulation of p53 predicts radioresistance leading to poor survival in patients with endometrial carcinoma |
| Q39071997 | Acetazolamide triggers death inducing autophagy in T-47D breast cancer cells. |
| Q64230202 | Activation of TAp73 and inhibition of TrxR by Verteporfin for improved cancer therapy in mutant pancreatic tumors |
| Q37713569 | Activation of the proapoptotic Bcl-2 protein Bax by a small molecule induces tumor cell apoptosis |
| Q38934098 | Aggregation and Prion-Like Properties of Misfolded Tumor Suppressors: Is Cancer a Prion Disease? |
| Q30390766 | All-codon scanning identifies p53 cancer rescue mutations |
| Q90714266 | An N6-methyladenosine at the transited codon 273 of p53 pre-mRNA promotes the expression of R273H mutant protein and drug resistance of cancer cells |
| Q49481527 | An in silico approach in predicting the possible mechanism involving restoration of wild-type p53 functions by small molecular weight compounds in tumor cells expressing R273H mutant p53. |
| Q34744590 | An inverse docking approach for identifying new potential anti-cancer targets. |
| Q41949931 | An open-label phase I dose-finding study of APR-246 in hematological malignancies. |
| Q36562253 | Anti-cancer efficacy of SREBP inhibitor, alone or in combination with docetaxel, in prostate cancer harboring p53 mutations |
| Q46577501 | Anti-leukaemic effects induced by APR-246 are dependent on induction of oxidative stress and the NFE2L2/HMOX1 axis that can be targeted by PI3K and mTOR inhibitors in acute myeloid leukaemia cells |
| Q35014385 | Awakening guardian angels: drugging the p53 pathway |
| Q38282236 | Battle against cancer: an everlasting saga of p53. |
| Q26749008 | Chemical Variations on the p53 Reactivation Theme |
| Q34079481 | Chronic inflammation and cancer: potential chemoprevention through nuclear factor kappa B and p53 mutual antagonism |
| Q89651152 | Clonal hematopoiesis in cancer |
| Q24628577 | Computational identification of a transiently open L1/S3 pocket for reactivation of mutant p53 |
| Q36254067 | Crude Extracts, Flavokawain B and Alpinetin Compounds from the Rhizome of Alpinia mutica Induce Cell Death via UCK2 Enzyme Inhibition and in Turn Reduce 18S rRNA Biosynthesis in HT-29 Cells |
| Q24600818 | DNA damage in oocytes induces a switch of the quality control factor TAp63α from dimer to tetramer |
| Q37281885 | Death inducing and cytoprotective autophagy in T‐47D cells by two common antibacterial drugs: sulphathiazole and sulphacetamide |
| Q50316561 | Delineating Crosstalk Mechanisms of the Ubiquitin Proteasome System That Regulate Apoptosis |
| Q61449903 | Deregulation and Targeting of TP53 Pathway in Multiple Myeloma |
| Q92856196 | Direct and Indirect Targeting of HOXA9 Transcription Factor in Acute Myeloid Leukemia |
| Q38060840 | Diverse Functional Roles of Reactive Cysteines |
| Q91964954 | Do Mutations Turn p53 into an Oncogene? |
| Q37845248 | Drug therapy of cancer |
| Q38191796 | Drugging the p53 pathway: understanding the route to clinical efficacy |
| Q26752823 | Drugging the undruggables: exploring the ubiquitin system for drug development |
| Q28077156 | Emerging Non-Canonical Functions and Regulation by p53: p53 and Stemness |
| Q34117634 | Extremely high Tp53 mutation load in esophageal squamous cell carcinoma in Golestan Province, Iran |
| Q89782502 | Follow the Mutations: Toward Class-Specific, Small-Molecule Reactivation of p53 |
| Q38820037 | Full-length p53 tetramer bound to DNA and its quaternary dynamics |
| Q36147271 | Function of hyperekplexia‐causing α1R271Q/L glycine receptors is restored by shifting the affected residue out of the allosteric signalling pathway |
| Q90269165 | Functional Classification of TP53 Mutations in Acute Myeloid Leukemia |
| Q55515721 | Gain-of-Function (GOF) Mutant p53 as Actionable Therapeutic Target. |
| Q38325068 | Gene transfection enhanced by ultrasound exposure combined with drug treatment guided by gene chip analysis |
| Q64243102 | HER2-Targeted Tyrosine Kinase Inhibitors Cause Therapy-Induced-Senescence in Breast Cancer Cells |
| Q84977200 | Hypoxia, Mn-SOD and H2O2 regulate p53 reactivation and PRIMA-1 toxicity irrespective of p53 status in human breast cancer cells |
| Q53691994 | Hypoxia-Induced Cisplatin Resistance in Non-Small Cell Lung Cancer Cells Is Mediated by HIF-1α and Mutant p53 and Can Be Overcome by Induction of Oxidative Stress. |
| Q36198159 | Hypoxic resistance of KRAS mutant tumor cells to 3-Bromopyruvate is counteracted by Prima-1 and reversed by N-acetylcysteine |
| Q38727892 | ID4 regulates transcriptional activity of wild type and mutant p53 via K373 acetylation |
| Q44483891 | Identification of two reactive cysteine residues in the tumor suppressor protein p53 using top-down FTICR mass spectrometry |
| Q46277999 | Inhibiting system xC- and glutathione biosynthesis - a potential Achilles' heel in mutant-p53 cancers. |
| Q37736385 | Inhibiting the system xC-/glutathione axis selectively targets cancers with mutant-p53 accumulation |
| Q58714397 | Inhibition of the glutaredoxin and thioredoxin systems and ribonucleotide reductase by mutant p53-targeting compound APR-246 |
| Q36413546 | Involvement of p53 in insulin-like growth factor binding protein-3 regulation in the breast cancer cell response to DNA damage |
| Q99712014 | Key Players in the Mutant p53 Team: Small Molecules, Gene Editing, Immunotherapy |
| Q58772571 | Landscape of somatic mutations in gastric cancer assessed using next-generation sequencing analysis |
| Q54428508 | MDM2 gene amplification in colorectal cancer is associated with disease progression at the primary site, but inversely correlated with distant metastasis |
| Q37732974 | MYC in oncogenesis and as a target for cancer therapies |
| Q38087850 | Mapping genetic alterations causing chemoresistance in cancer: identifying the roads by tracking the drivers |
| Q47286853 | Master regulatory role of p63 in epidermal development and disease |
| Q30374671 | Misfolding, Aggregation, and Disordered Segments in c-Abl and p53 in Human Cancer. |
| Q64054715 | Mitochondrially targeted p53 or DBD subdomain is superior to wild type p53 in ovarian cancer cells even with strong dominant negative mutant p53 |
| Q92445781 | Molecular Determinants of Cancer Therapy Resistance to HDAC Inhibitor-Induced Autophagy |
| Q28074490 | Molecular Mechanisms of p53 Deregulation in Cancer: An Overview in Multiple Myeloma |
| Q39393193 | Molecularly targeted therapies for p53-mutant cancers |
| Q84715351 | Monosomal karyotype routinely defines a poor prognosis subgroup in acute myeloid leukemia and is frequently associated withTP53deletion |
| Q34978872 | Mutant p53 Protein Is Targeted by Arsenic for Degradation and Plays a Role in Arsenic-mediated Growth Suppression |
| Q30354662 | Mutant p53 Protein and the Hippo Transducers YAP and TAZ: A Critical Oncogenic Node in Human Cancers. |
| Q33687048 | Mutant p53 gain-of-function in cancer |
| Q64892305 | Mutant p53 in cancer therapy-the barrier or the path. |
| Q38197826 | Mutant p53 in cancer: new functions and therapeutic opportunities |
| Q98280914 | Mutant p53 induces Golgi tubulo-vesiculation driving a prometastatic secretome |
| Q45906744 | Mutant p53 reactivation by PRIMA-1MET induces multiple signaling pathways converging on apoptosis. |
| Q26770576 | Mutant p53: One, No One, and One Hundred Thousand |
| Q55504431 | Mutations of p53 decrease sensitivity to the anthracycline treatments in bladder cancer cells. |
| Q38657267 | New Phage Display-Isolated Heptapeptide Recognizing the Regulatory Carboxy-Terminal Domain of Human Tumour Protein p53. |
| Q49962911 | New therapeutic strategies to treat human cancers expressing mutant p53 proteins |
| Q52859512 | Novel p53 therapies for head and neck cancer |
| Q34103213 | OncodriveROLE classifies cancer driver genes in loss of function and activating mode of action |
| Q26749382 | Oncogenic Intra-p53 Family Member Interactions in Human Cancers |
| Q38846785 | Oncogenic Mutant p53 Gain of Function Nourishes the Vicious Cycle of Tumor Development and Cancer Stem-Cell Formation |
| Q38156100 | Oncoprotein stabilization in brain tumors. |
| Q27021759 | P53 mutations in colorectal cancer - molecular pathogenesis and pharmacological reactivation |
| Q48507317 | PARP-1 inhibitors sensitize HNSCC cells to APR-246 by inactivation of thioredoxin reductase 1 (TrxR1) and promotion of ROS accumulation |
| Q47274927 | PRIMA-1 and PRIMA-1Met (APR-246): From Mutant/Wild Type p53 Reactivation to Unexpected Mechanisms Underlying Their Potent Anti-Tumor Effect in Combinatorial Therapies |
| Q47371251 | PRIMA-1 induces p53-mediated apoptosis by upregulating Noxa in esophageal squamous cell carcinoma with TP53 missense mutation. |
| Q37641688 | PRIMA-1 targets the vulnerability of multiple myeloma of deregulated protein homeostasis through the perturbation of ER stress via p73 demethylation |
| Q35805485 | PRIMA-1(MET) induces death in soft-tissue sarcomas cell independent of p53. |
| Q38994024 | PRIMA-1, a mutant p53 reactivator, induces apoptosis and enhances chemotherapeutic cytotoxicity in pancreatic cancer cell lines |
| Q64239929 | PRIMA-1-induced neuroblastoma cell death is modulated by p53 and mycn through glutathione level |
| Q36738640 | PRIMA-1MET induces apoptosis through accumulation of intracellular reactive oxygen species irrespective of p53 status and chemo-sensitivity in epithelial ovarian cancer cells |
| Q39659292 | PRIMA-1MET/APR-246 targets mutant forms of p53 family members p63 and p73 |
| Q38895818 | PRIMA-1Met induces apoptosis in Waldenström's Macroglobulinemia cells independent of p53. |
| Q37696259 | PRIMA-1Met suppresses colorectal cancer independent of p53 by targeting MEK |
| Q36546764 | PRIMA-1met (APR-246) inhibits growth of colorectal cancer cells with different p53 status through distinct mechanisms |
| Q100762002 | Pharmacologic profiling of patient-derived xenograft models of primary treatment-naïve triple-negative breast cancer |
| Q37191174 | Pharmacological Activation of p53 in Cancer Cells |
| Q30389604 | Pharmacological reactivation of mutant p53: from protein structure to the cancer patient |
| Q38286198 | Pharmacological reactivation of p53 as a strategy to treat cancer. |
| Q50014672 | Pharmacoperones as Novel Therapeutics for Diverse Protein Conformational Diseases |
| Q49952370 | Piperlongumine and p53-reactivator APR-246 selectively induce cell death in HNSCC by targeting GSTP1. |
| Q52584348 | Potential therapeutic targets of TP53 gene in the context of its classically canonical functions and its latest non-canonical functions in human cancer |
| Q33503650 | Predicting positive p53 cancer rescue regions using Most Informative Positive (MIP) active learning |
| Q92254379 | Present and Future Prospect of Small Molecule & Related Targeted Therapy Against Human Cancer |
| Q51679220 | Proteasome machinery is instrumental in a common gain-of-function program of the p53 missense mutants in cancer. |
| Q35050328 | RB1 status in triple negative breast cancer cells dictates response to radiation treatment and selective therapeutic drugs |
| Q93116701 | Rational design using sequence information only produces a peptide that binds to the intrinsically disordered region of p53 |
| Q26800059 | Reactivating mutant p53 using small molecules as zinc metallochaperones: awakening a sleeping giant in cancer |
| Q39673538 | Reactivation of mutant p53: Constraints on mechanism highlighted by principal component analysis of the DNA binding domain |
| Q39529355 | Reactivation of p53 mutants by prima-1 [corrected] in thyroid cancer cells. |
| Q26740191 | Redox Homeostasis and Cellular Antioxidant Systems: Crucial Players in Cancer Growth and Therapy |
| Q37861632 | Redox modulation of p53: Mechanisms and functional significance |
| Q36733743 | Restoration of DNA-binding and growth-suppressive activity of mutant forms of p53 via a PCAF-mediated acetylation pathway |
| Q37818291 | Restoring p53 Tumor Suppressor Activity As an Anticancer Therapeutic Strategy |
| Q57084678 | Resveratrol prevents p53 aggregation and in breast cancer cells |
| Q39205536 | Reviving the guardian of the genome: Small molecule activators of p53. |
| Q37690890 | Role of Autophagy and Apoptosis in Non-Small-Cell Lung Cancer |
| Q38161342 | Role of p53 in Cell Death and Human Cancers |
| Q33795918 | SCH529074, a small molecule activator of mutant p53, which binds p53 DNA binding domain (DBD), restores growth-suppressive function to mutant p53 and interrupts HDM2-mediated ubiquitination of wild type p53 |
| Q92955391 | SOCS1: phosphorylation, dimerization and tumor suppression |
| Q27027835 | Small molecule compounds targeting the p53 pathway: are we finally making progress? |
| Q27677872 | Small molecule induced reactivation of mutant p53 in cancer cells |
| Q34096644 | Small molecule structure correctors abolish detrimental effects of apolipoprotein E4 in cultured neurons. |
| Q36070528 | Small-Molecule NSC59984 Restores p53 Pathway Signaling and Antitumor Effects against Colorectal Cancer via p73 Activation and Degradation of Mutant p53. |
| Q30421643 | Small-Molecule Structure Correctors Target Abnormal Protein Structure and Function: Structure Corrector Rescue of Apolipoprotein E4–Associated Neuropathology |
| Q47995141 | Small-molecule stabilization of the p53 - 14-3-3 protein-protein interaction. |
| Q41453979 | Stabilization of mutant p53 via alkylation of cysteines and effects on DNA binding |
| Q36904012 | Strong synergy with APR-246 and DNA-damaging drugs in primary cancer cells from patients with TP53 mutant High-Grade Serous ovarian cancer |
| Q34687279 | Suppression of Glucosylceramide Synthase Restores p53-Dependent Apoptosis in Mutant p53 Cancer Cells |
| Q50026245 | Synergistic and additive effect of retinoic acid in circumventing resistance to p53 restoration |
| Q35646576 | TP53 transcription factor for the NEDD9/HEF1/Cas-L gene: potential targets in Non-Small Cell Lung Cancer treatment. |
| Q26770856 | Targeting Oncogenic Mutant p53 for Cancer Therapy |
| Q64056701 | Targeting Oxidative Stress With Auranofin or Prima-1 to Circumvent p53 or Bax/Bak Deficiency in Myeloma Cells |
| Q89157968 | Targeting Transcription Factors for Cancer Treatment |
| Q47291772 | Targeting mutant p53 for efficient cancer therapy. |
| Q26766341 | Targeting of Mutant p53 and the Cellular Redox Balance by APR-246 as a Strategy for Efficient Cancer Therapy |
| Q34636996 | Targeting p53 by small molecules in hematological malignancies |
| Q33655329 | Targeting p53 for Novel Anticancer Therapy |
| Q37506032 | Targeting the LKB1 tumor suppressor |
| Q91643844 | Targeting the Oncogenic p53 Mutants in Colorectal Cancer and Other Solid Tumors |
| Q35795073 | Targeting the p53 signaling pathway in cancer therapy – the promises, challenges and perils |
| Q38861978 | The "Jekyll and Hyde" Actions of Nucleic Acids on the Prion-like Aggregation of Proteins |
| Q39043141 | The Complex Link between Apoptosis and Autophagy: a Promising New Role for RB. |
| Q41891513 | The Genomics of Lung Adenocarcinoma: Opportunities for Targeted Therapies |
| Q38858580 | The MDM2-inhibitor Nutlin-3 synergizes with cisplatin to induce p53 dependent tumor cell apoptosis in non-small cell lung cancer |
| Q58761640 | The Mutant p53-Targeting Compound APR-246 Induces ROS-Modulating Genes in Breast Cancer Cells |
| Q37631697 | The Potential of Targeting Ribosome Biogenesis in High-Grade Serous Ovarian Cancer |
| Q99708992 | The Undervalued Avenue to Reinstate Tumor Suppressor Functionality of the p53 Protein Family for Improved Cancer Therapy-Drug Repurposing |
| Q38186535 | The aggregation of mutant p53 produces prion-like properties in cancer |
| Q49571721 | The curcumin analog HO-3867 selectively kills cancer cells by converting mutant p53 protein to transcriptionally active wildtype p53. |
| Q34786538 | The induction of the p53 tumor suppressor protein bridges the apoptotic and autophagic signaling pathways to regulate cell death in prostate cancer cells |
| Q37808944 | The missing Zinc: p53 misfolding and cancer |
| Q60955775 | The molecular mechanism of action of methylene quinuclidinone and its effects on the structure of p53 mutants |
| Q36659339 | The molecular pathogenesis of head and neck squamous cell carcinoma |
| Q57162865 | The p53 Pathway in Glioblastoma |
| Q27690770 | The p53 pathway as a target in cancer therapeutics: obstacles and promise |
| Q92025183 | The p53/MDM2/MDMX-targeted therapies-a clinical synopsis |
| Q92496678 | The role of TP53 in acute myeloid leukemia: Challenges and opportunities |
| Q28072553 | The role of p53 in cancer drug resistance and targeted chemotherapy |
| Q37762069 | The tumor suppressor p53: from structures to drug discovery |
| Q91898958 | Therapeutic targeting of mutant p53 in pediatric acute lymphoblastic leukemia |
| Q92365312 | Therapeutic targeting of mutated p53 in acute lymphoblastic leukemia |
| Q37948547 | Therapeutic targets in head and neck squamous cell carcinoma: Identification, evaluation, and clinical translation |
| Q28485155 | Transient transfection of a wild-type p53 gene triggers resveratrol-induced apoptosis in cancer cells |
| Q35708113 | Translational approaches targeting the p53 pathway for anti‐cancer therapy |
| Q39218376 | Understanding cell cycle and cell death regulation provides novel weapons against human diseases. |
| Q37802195 | Understanding wild-type and mutant p53 activities in human cancer: new landmarks on the way to targeted therapies |
| Q36782143 | Using a preclinical mouse model of high-grade astrocytoma to optimize p53 restoration therapy. |
| Q37323049 | Variability in functional p53 reactivation by PRIMA-1(Met)/APR-246 in Ewing sarcoma. |
| Q58760242 | Virtual screening using covalent docking to find activators for G245S mutant p53 |
| Q92318780 | Which are the most promising targets for minimal residual disease-directed therapy in acute myeloid leukemia prior to allogeneic stem cell transplant? |
| Q39109300 | p28, an Anionic Cell-Penetrating Peptide, Increases the Activity of Wild Type and Mutated p53 without Altering Its Conformation |
| Q39634867 | p53 Dysfunction by Xeroderma Pigmentosum Group C Defects Enhance Lung Adenocarcinoma Metastasis via Increased Mmp1 Expression |
| Q33852683 | p53 abnormalities and potential therapeutic targeting in multiple myeloma |
| Q48117580 | p53 and NF 1 loss plays distinct but complementary roles in glioma initiation and progression |
| Q92500329 | p53 as a hub in cellular redox regulation and therapeutic target in cancer |
| Q37707387 | p53 family: Therapeutic targets in neuroblastoma |
| Q34616697 | p53 governs telomere regulation feedback too, via TRF2 |
| Q38069463 | p53 mutations in cancer |
| Q28478414 | p53 transactivation and the impact of mutations, cofactors and small molecules using a simplified yeast-based screening system |
| Q37750115 | p53-based cancer therapy |
| Q28611414 | p73 as a Pharmaceutical Target for Cancer Therapy |
Search more.